GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing CtDNA Diagnostics - Colorectal Cancer
GUIding Multi-moDal ThErapies Against MRD by Liquid Biopsies in Colorectal Cancer - GUIDE.MRD-01-CRC
Claus Lindbjerg Andersen
590 participants
Aug 1, 2023
OBSERVATIONAL
Conditions
Summary
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough. There is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points. The GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient. GUIDE.MRD-01-CRC is a part of the GUIDE.MRD project.
Eligibility
Inclusion Criteria7
- Colorectal cancer stage III
- Colorectal cancer, UICC stage III
- Has received curative-intent resection and is a candidate for adjuvant chemotherapy
- Patient able to understand and sign written informed consent
- Colorectal cancer liver metastasis
- Planned for curative-intent treatment
- Performance status 0-1
Exclusion Criteria15
- Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome
- Inflammatory bowel disease (Crohn's disease or ulcerative colitis)
- Verified distant metastases
- Not treated with adjuvant chemotherapy despite indication (incomplete treatment not included)
- Treated with neoadjuvant chemo-radiation therapy
- No tissue sample available for the project, or tumor content in the tissue sample is \<20%
- Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma)
- Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening
- Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study
- Colorectal cancer liver metastasis
- Liver cirrhosis
- Extrahepatic metastases
- Other cancer within the last 5 years
- Intervention not performed with curative intent
- No tissue available from CRLM or primary tumor
Locations(15)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06111105